+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Orthobiologics Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4617263
  • Report
  • 115 pages
  • Mordor Intelligence
until Jul 01st 2019
1 of 5


  • Arthrex Inc.
  • Bone Support
  • Globus Medical Inc.
  • Integra Lifesciences
  • Medtronic PLC
  • NuVasive Inc.
  • MORE
Market Overview

The orthobiologics market was valued at USD 4,747.1 million in 2018 and is expected to reach USD 5,983.82 million by 2024, with an anticipated CAGR of 4.92% during the forecast period (2019-2024).

The major factors attributing to the growth of the orthobiologics market are increased incidences of sports injury, road accidents, and osteoarthritis, rising obese and geriatric population, and increasing adoption of minimally invasive surgeries. The global increase in the number of geriatrics and obese people is likely to lead to consequences, like greater incidences of osteoarthritis. Consequently, the geriatric population and population with obesity are at higher risk of musculoskeletal disorders. According to the United Nations report in 2017, there were an estimated 962 million people aged 60 or over in the world, comprising 13% of the global population. The population aged 60 or above is growing at a rate of about 3% per year. It was estimated that Europe had the highest percentage of the population aged 60 or over in 2017. Thus, the rise in geriatric and obese population is acting as a major driver for the growth of orthobiologics market.

Scope of the Report

Orthobiologics are used by orthopedic surgeons to help injuries heal more quickly. They are used to quicken the healing of broken bones and injured muscles, tendons, and ligaments. These products are made from substances that are naturally found in our body.

Key Market Trends

Osteoarthritis and Degenerative Arthritis Segment, by Application, is Expected to Experience the Fastest Growth in the Market

Osteoarthritis (OA) is a weakening disease that affects 20% of the world’s population, according to the United Nations in 2017. Nearly 130 million are estimated to suffer from OA, out of which 40 million are estimated to be severely disabled by the disease. According to the Arthritis Foundation in 2017, an estimated 30.8 million adults are suffering from osteoarthritis. It is the most common cause of disability in adults.

Due to the increasing prevalence of OA, there is an urgent need for better understanding of the disease pathophysiology, improved early detection, strategies for disease prevention, and early management. Orthobiologics can be one such option for the treatment of OA. According to the American Academy of Orthopaedic Surgeons (AAOS), orthobiologics are biological substances found naturally in the body that help to heal injuries. These treatments include platelet-rich plasma (PRP), prolotherapy, ozone therapy, autologous conditioned serum (ACS), and many others. With the increasing prevalence of OA, as well as the development of innovative products, the market growth is expected to be augmented.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market throughout the forecast period. This is due to the increasing incidences of spinal disorders, rising geriatric and obese population, growing preference for minimally invasive procedures, and increasing physician and patient awareness about newly introduced treatment procedures and technologies. In the North American region, the United States holds the largest market share.

Competitive Landscape

The orthobiologics market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising patient awareness levels and high prevalence of diseases, few other smaller players are expected to enter into the market in the coming years. Some of the major players of the market are Sanofi, Stryker, Zimmer Biomet, Seaspine Holdings Corporation, and Medtronic, among others.

As part of this package, any purchases made up to 30th June will receive the following:

1) Free update of the report in 6 months on request 

2) Free Market Estimate sheet excel data sheet
Note: Product cover images may vary from those shown
2 of 5


  • Arthrex Inc.
  • Bone Support
  • Globus Medical Inc.
  • Integra Lifesciences
  • Medtronic PLC
  • NuVasive Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Sports Injuries and Road Accidents
4.2.2 Increasing Incidence of Osteoarthritis
4.2.3 Increasing Geriatric and Obese Population
4.2.4 Increasing Patient Preference for Minimally Invasive Procedures
4.3 Market Restraints
4.3.1 High Costs Associated with Orthobiologic-based Treatments
4.3.2 Preference for Alternative Treatment Options
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Products
5.1.1 Viscosupplementation Products
5.1.2 Demineralized Bone Matrices
5.1.3 Synthetic Orthobiologics
5.1.4 Bone Morphogenic Protein
5.1.5 Allografts
5.1.6 Plasma-rich Protein
5.1.7 Bone Marrow Aspirate Concentrate
5.2 By Application
5.2.1 Osteoarthritis and Degenerative Arthritis
5.2.2 Spinal Fusion
5.2.3 Soft-tissue Injuries
5.2.4 Fracture Recovery
5.2.5 Maxillofacial and Dental Applications
5.3 By End User
5.3.1 Hospitals, Orthopedic Clinics, and Ambulatory Care Centers
5.3.2 Research and Academic Institutes
5.3.3 Dental Clinics and Facilities
5.4 Geography
5.4.1 North America US Canada Mexico
5.4.2 Europe Germany UK France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Arthrex Inc.
6.1.2 Sanofi
6.1.3 DePuy Synthes (A Subsidiary of Johnson & Johnson)
6.1.4 Globus Medical Inc.
6.1.5 Terumo Corporation
6.1.6 Stryker Corporation
6.1.7 Zimmer Biomet
6.1.8 Medtronic PLC
6.1.9 NuVasive Inc.
6.1.10 Integra Lifesciences
6.1.11 Bone Support
6.1.12 Seaspine Holdings Corporation

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • Arthrex Inc.
  • Sanofi
  • DePuy Synthes (A Subsidiary of Johnson & Johnson)
  • Globus Medical Inc.
  • Terumo Corporation
  • Stryker Corporation
  • Zimmer Biomet
  • Medtronic PLC
  • NuVasive Inc.
  • Integra Lifesciences
  • Bone Support
  • Seaspine Holdings Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4617263